MediciNova (MNOV) Leaps on FDA Nod

MediciNova, Inc MNOV shares climbed 46.2% to $5.13 after the company reported the FDA approval of the second Phase 2 protocol for MN-001 in NASH which targets NASH patients with hypertriglyceridemia. Share volume was 355,000, compared to an all-day average of 8,100